Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Vaccine
; 31(43): 4968-74, 2013 Oct 09.
Article
in En
| MEDLINE
| ID: mdl-23954380
Key words
4CMenB vaccine strain coverage; CC; ELISA; FN; FP; HPA; Health Protection Agency; IMD; MATS; MLST; MenB; Meningococcal Antigen Typing System; NHBA; NadA; Neisseria meningitidis serogroup B; Neisserial adhesin A; Neisserial heparin binding antigen; OMV; PBT; PorA; RP; SBA; ST; Serum bactericidal antibody assay; Stratified proportional sampling; TN; TP; capsular group B meningococcus; clonal complex; enzyme-linked immunosorbent assay; fHBP; factor H binding protein; false negatives; false positives; hSBA; invasive meningococcal disease; multilocus sequence typing; outer membrane vesicle; porin A; positive bactericidal threshold; relative potency; sequence type; serum bactericidal antibody; serum bactericidal antibody assay with human complement; true negatives; true positives
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccination
/
Meningococcal Vaccines
/
Neisseria meningitidis, Serogroup B
/
Serum Bactericidal Antibody Assay
/
Antibodies, Bacterial
/
Antigens, Bacterial
Type of study:
Evaluation_studies
/
Prognostic_studies
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Vaccine
Year:
2013
Document type:
Article
Country of publication:
Países Bajos